Terms and Conditions for the EUCAIM open Call

Table of Contents

These terms and conditions cover the EUCAIM Open Call to include new beneficiaries into the EUCAIM consortium for data incorporation and AI training, benchmarking and validation use cases.

1. The Open Call

1.1 The EUCAIM project (EC Grant Agreement 101100633) is deploying a pan-European infrastructure (Cancer Image Europe) for cancer images, related clinical data, and AI tools for processing and analysis (the “Project”). 

1.2 The consortium of the Project is made up of 76 partners (the “EUCAIM Consortium” or the “Organizer”). You may learn more about the EUCAIM Consortium and the Project on the following website: www.cancerimage.eu.

1.3 The Consortium is organizing an Open Call to encourage onboarding new cancer image data holders, and new reliable AI algorithms to be validated and tested on the cancer image data of the repository.

1.4 The Open Call will take place from 9 April 2024 until 10 June 2024. For more details on the timeline of the Open Call, please consult the Open Call text here.

2. Eligibility

2.1 The Open Call is open to legal entities eligible for participation in the European Commission’s Digital Europe Programme as per the eligibility criteria of 2022.

2.2 Participation in the Open Call constitutes the Participant’s full and unconditional agreement to and acceptance of these terms and conditions, otherwise referred to as rules of the Open Call (“Terms”). The term “you” refers to you, the “Participant”. 

2.3 Members or employees of the EUCAIM Consortium partners and their respective companies, affiliates, and subsidiaries, or individuals providing services to them during the Open Call, are not eligible to participate in the Open Call.

2.4 Data Holders must guarantee that data is anonymized. Participation in the Open Call is precluded to any individual that may have access to additional information (as established under Article 4.5 of  Regulation (EU) no. 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regards to the processing of personal data and on the free movement of such data, the “GDPR”) that under reasonable means would allow to attribute the Data (as defined in Clause 5.1 of this Terms) to specific data subjects. By accepting these Terms, Participants declare that they have no access to information that may allow for the identification of data subjects and that they are not in violation of this provision.

3. Application

3.1 Applications will be accepted from 9 April 2024 until the end of the Application Period.

3.2 Applications will be assessed by the Access Committee of the Organizer, as described in the Open Call text, section 2.3 and Annex 1. Eligible applications will be evaluated by the EUCAIM Access Committee, which will rank the Applications based on scientific quality and technical requirements. The highest ranked applications will be shortlisted and recommended for accession to the EUCAIM Grant Agreement. For the shortlisted applicants, the European Commission will perform formal eligibility checks.

3.3 After evaluation by the Access Committee, the Organizer will notify the selected Participants of their acceptance to become new beneficiaries of the EUCAIM project and will send data additional information per email, as established in Clause 8.1.

3.4 The Organizer reserves the right to verify the eligibility of Participants and reserves the right of admission based on its sole discretion. 

3.5 Participants shall follow relevant institutional policies and applicable European and national laws and regulations (if any) concerning the completion of ethics review or approval that may be required for participation in the Open Call. When applicable due to their own circumstances, Participants shall submit an ethical approval validly issued by a duly accredited Ethics Committee and an ethical impact assessment (e.g. ALTAI methodology).

3.6 For more details on the applications process, please consult the Open Call text and the application form.

4. Participation

4.1 Details on technical requirements to be followed for participation in the Open Call, any clinical questions to be addressed by Participants, and the different phases of the Open Call can be found in the Open Call text, which are hereby incorporated by reference and read, accepted and agreed upon by the Participants’ participation in the Open Call.

4.2 Participants acknowledge and agree that acceptance of the terms and conditions of the Cancer Image Europe Platform, as well as, if the application is selected for funding, accession to the EUCAIM Grant Agreement and EUCAIM Consortium Agreement shall be required in order to participate in the EUCAIM consortium.

4.3 Successful Participants are obliged to implement their work during the EUCAIM project duration (ending December 2026) and must contribute to progress reports mandated by the European Commission, as part of the EUCAIM Grant Agreement.

4.4 Funding for Participants is released under the same conditions as the EUCAIM project partners, requiring 50% co-funding according to the Digital Europe Programme.

4.5 The Organizer will not reimburse any expenses or costs for Participants during the application phase.

5. Verification of Applications

5.1 After the Open Call submission deadline passed, Applications are evaluated by the Access Committee of the Organizer. Participants who submitted an Application that is selected for inclusion will be notified of next steps by email. Participants who submitted an unsuccessful Application will be notified as well.

5.2 Participants agree that the decision on inclusion shall be final and binding for all Participants and shall not be subject to dispute in a court of law. In accordance with Clause 4 above, other technical requisites to be followed for participation in the Open Call, duly disclosed to the Participants in the Open Call text may be taken into consideration by the Organizer for the selection of the successful Applications. Participants shall have no right to a justification of the decisions made by the Organizer.

5.3 Inclusions of Applicants into the EUCAIM consortium are subject to verification of administrative details and eligibility conditions of the Participants. 

5.4 The Organizer may deem a Participant ineligible if the Organizer reasonably believes that the Participant has attempted to undermine the legitimate operation of the Open Call by cheating, deception, or other unfair or dishonest practices.

5.5 In the event of a disqualification, the Organizer may proceed to include an alternate Participant.

5.6 The Organizer is not responsible for Applications not received due to lost, failed, delayed or interrupted connections or miscommunications or other electronic malfunctions.

6. Personal Data

6.1 The may collect personal data from the Participants (understood as information that relates to an identified or identifiable individual) in the application process. This personal data will only be used for communication by the Organizer with the Participants relating to the Open Call and any related information.

6.2 Explicit consent for any other uses of Participants’ personal data will be requested if needed.

6.3 By applying to the Open Call, Participants agree to give the Organizer access to the information they provide.

6.4 In accordance with GDPR, Participants may exercise their rights of access, rectification, erasure, restriction of processing, objection and portability by contacting the Organizer via email. 

6.5 Privacy Policies of the Cancer Image Europe Platform apply. 

7. Confidentiality

7.1 Any Confidential Information disclosed by the Organizer to Participants in connection with the Open Call:

7.1.1 shall be used by Participants exclusively for participation in the Open Call;

7.1.2 must not be distributed or disclosed in any way or form by Participants;

7.1.3 must be kept confidential by Participants.

7.2 “Confidential Information” means any information and data, including, but not limited to, the Data (as defined in Clause 5.1 of this Terms), any kind of business, commercial, code, dataset or technical information, and data disclosed in connection with the Open Call irrespective of the medium in which such information or data is embedded. 

7.3 After the Open Call (or any time before upon request by the Organizer), the Participants must destroy all Confidential Information disclosed by the Organizer in their possession, including Confidential Information stored electronically and/or on record-bearing media as well as any copies thereof.

8. Data

8.1 Upon successful evaluation and inclusion in the EUCAIM consortium, Participants will have access to the Cancer Image Europe Platform, where certain original and associated clinical data, together with image (pre-) processing tools, harmonization tools and analysis tools will be shared with the Participants (the “Data”).

8.2 Data remains the sole property of the Data Holder in question if the Data is shared as a federated node. If Data is anonymized and transferred to the EUCAIM central nodes, EUCAIM will become the Data Holder. Participants acknowledge and accept that they will not acquire any intellectual property right or any other right over the Data and the EUCAIM platform services, other than as set forth herein. 

8.3 The Organizer grants the Participants a royalty-free, non-sublicensable, non-transferable, non-commercial, non-exclusive, revocable license to use the Data to address the proposed work submitted as part of the Open Call application.

8.4 Participants expressly agree to exclusively use the provided Data for implementation of their proposed work in the Open Call application and not to distribute, transfer, share or disclose it in any way or form. 

8.5 Participants will not reverse engineer, decompile or disassemble the components of the Cancer Image Europe Platform, or encourage or assist any third party in doing so.

8.6 Participants will not, either alone or in concert with any other information, make any effort to identify or contact individuals who are or may be the source of the information in the Data, and are strictly prohibited from generating or using images or comparable representations of the face, head, or body for facial recognition, reidentification, or other purposes that could allow the identities of individuals to be readily ascertained.

9. Intellectual Property

9.1 Participants agree not to make any Application that infringes any third-party proprietary rights, intellectual property rights, industrial property rights, personal or moral rights, or any other rights, including, without limitation, copyright, patent, trade secret, privacy or confidentiality obligations.

9.2 The ownership of any intellectual property developed by the Participants during and within the scope of the EUCAIM Project will remain with the Participants. 

9.3 By participating in the Open Call, Participants expressly authorize the Organizer to, within the scope of the Project, publish, communicate, and disclose orally, graphically, or in writing, and with no compensation involved, summary information about their Application.

9.4 The Participants shall not acquire any full or partial intellectual property right (or any other rights of any kind) over the Project, the Cancer Image Europe Platform or the Consortium, nor on any names or trademarks associated with them, used alone, in association with or as part of another word or name.

10. License

10.1. If necessary, terms for licensing will be negotiated individually between the selected Participants and the Organizer under fair conditions.

11. Representations & Warranties

11.1. Participants represent and warrant that:

11.1.1. Submission of your Application within the scope of your participation in the Open Call does not violate the privacy rights, publicity rights, copyrights, contract rights, or any other rights of any person.

11.1.2. The Applications will not cause the Organizer to breach any law, regulation, code, or other legal obligation and will not or could not be reasonably considered defamatory, disparaging, seditious, offensive, threatening, abusive, in breach of confidence or breach of privacy.

12. Termination

12.1 The Organizer may terminate your participation in the Open Call in writing (by email) if you breach these Terms. This termination will take effect immediately after such termination email has been sent.

12.2 The Organizer shall not be liable to you or any third party for any claims or damages arising out of any termination or suspension, or any other actions taken by the Organizer in connection therewith.

12.3 Participants may drop out of the Open Call and forego any further participation.

13. Miscellaneous

13.1 Computer “hacking” is unlawful. If any Participant attempts to compromise the integrity or the legitimate operation of the Open Call by hacking or by cheating or committing fraud in any way, the Organizer may claim damages to the fullest extent permitted by law.

13.2 The Organizer reserves the right to modify these Terms at any time, without warning or notice, and to suspend, withdraw or cancel the Open Call for any reason and at any time, at its sole discretion and without incurring any liability. 

13.3 The execution of the Open Call and the interpretation and enforcement of these Terms shall be exclusively governed by and construed by the laws of Austria. Any conflict regarding the Open Call or these Terms shall be subject to the exclusive jurisdiction of the courts of Austria.

13.4 If you have any questions about these Terms, please get in touch with us via [email protected].

 

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Find out more

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

WATCH THE RECORDING

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

Sign up for more information

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.

Participate